Current Oncology, Volume 16, Issue 5

Lay people, particularly people in the press, frequently ask the question “When will we cure cancer?” I believe that we will never cure cancer [...]

The 4th annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake focused on the themes of innovations in the management of lung cancer, controversies in the management of esophageal cancer, and molecular targeted therapies in lung cancer. Thi...

Objective: The aim of the present study was to survey human resources personnel about how their northeastern Ontario workplaces assist employees with cancer. Study Design and Setting: This cross-sectional study was conducted from December 2007 to Apr...

Background: Standard treatment for differentiated thyroid cancer is thyroidectomy followed in selected cases by radioiodine ablation (ra). Recombinant humanized thyroid-stimulating hormone (rhtsh) is an exogenous source of tsh that can be administere...

Medullary thyroid carcinoma (mtc) is a rare cancer (less than 8% of all thyroid cancers) that occurs both as a familial and as a sporadic disease [...]

Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of ¹³¹I–tositumomab in non-Hodgkin lymphoma (nhl) have suggested benefit in patients with relapsed...

Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the i...

Introduction: Our study examined the wait time from ready-to-treat to radiation therapy for cohorts of breast cancer patients requiring adjuvant radiation therapy in 2001 and in 2005 after the implementation of strategies to reduce wait times for rad...

This integrative review critically examines quantitative and qualitative evidence concerning factors influencing the participation of Canadian women in mammography. Empirical studies published between 1980 and 2006 were identified and retrieved by se...

Treatment of patients with metastatic colorectal cancer has changed in recent years, with many patients now being offered intent-to-treat regimens. In this context, a multidisciplinary approach to the metastatic disease may lead to individualized tre...

Extramammary Paget disease is a rare intraepithelial neoplasm of the vulvar, penoscrotal, or perianal skin. No effective therapies for metastatic disease have been reported, and prognosis for metastatic disease is poor. Here, we report the case of an...

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available....

Oncogenic osteomalacia is a rare metabolic bone disease characterized by phosphate leakage from the kidney and subsequent hypophosphatemia. It is caused by a phosphaturic factor produced by certain tumours. Removal of such tumours can completely cure...

Background: The BC Cancer Agency Gastro-intestinal Tumor Group supports one standard of care (soc) chemotherapy regimen for metastatic esophagogastric adenocarcinoma—specifically, weekly cisplatin and 5-fluorouracil (5fu) infusion. All other regimens...

Background: Germline mutation screening of BRCA1 and BRCA2 genes is performed in suspected familial breast cancer cases, but a causative mutation is found in only 30% of patients. The development of additional methods to identify good candidates for...

Please be advised that there is an error in Table I of “The Role of HER2-targeted Therapies in Women with HER2-Overexpressing Metastatic Breast Cancer” by Dent et al. which appeared in Current Oncology Volume 16, Number 4 on page 236 in print, and pa...